USPTO Examiner PUTTLITZ KARL J - Art Unit 1646

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18904628ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOADOctober 2024July 2025Allow920YesNo
18896098ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUNDSeptember 2024March 2025Allow510NoNo
18802353COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAMEAugust 2024January 2025Allow610NoNo
18787110IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOFJuly 2024April 2025Allow921NoNo
18731223LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONSMay 2024January 2025Allow820YesNo
18656166ANTIBODIES TARGETING LIV-1 AND USES THEREOFMay 2024August 2024Allow300YesNo
18648976ANTIBODY AGAINST ADVANCED GLYCATION END PRODUCTS AND USE THEREOFApril 2024September 2024Allow500YesNo
18411436ANTI-CD37 ANTIBODY-DRUG CONJUGATEJanuary 2024July 2024Allow601YesNo
18393436VACCINIA VIRUS RECOMBINANT A33R PROTEIN AND KIT FOR DIAGNOSING ANTIBODIES AGAINST ORTHOPOXVIRUS COMPRISING THE SAMEDecember 2023November 2024Allow1110NoNo
18511591ANTI-B7H3 ANTIBODY-DRUG CONJUGATE AND USE THEREOFNovember 2023June 2024Allow710YesNo
18366183METHOD OF TREATING POST-TRAUMATIC STRESS DISORDERAugust 2023May 2025Allow2120YesNo
18225567PROTEIN-ANTIVIRAL COMPOUND CONJUGATESJuly 2023February 2025Allow1910YesNo
18320869ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOFMay 2023March 2025Abandon2210NoNo
18118105THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOFMarch 2023December 2024Allow2120NoNo
18117089ANTIBODY-DRUG CONJUGATEMarch 2023June 2024Allow1600NoNo
18175148AMANITIN CONJUGATESFebruary 2023September 2024Allow1910NoNo
18160012COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B-TARGETED THERAPYJanuary 2023November 2024Abandon2110NoNo
18080079Methods For Treating HypersomniaDecember 2022October 2024Abandon2210NoNo
18072963PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENSDecember 2022March 2025Allow2710NoNo
17990485SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATESNovember 2022October 2024Abandon2310NoNo
17988595POLYMER LINKERS AND THEIR USESNovember 2022February 2025Allow2710YesNo
17924253COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENEIC CELLS USING SIMIAN ICP47 AND VARIANTS THEREOFNovember 2022May 2025Abandon3100NoNo
17822638Conjugates for Targeted Cell Surface EditingAugust 2022April 2025Allow3220YesNo
17878049CELL SURFACE ANCHORING ANTIGEN CONJUGATES TO TREAT CANCERAugust 2022May 2025Abandon3421NoNo
17814728ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONSJuly 2022November 2024Allow2720NoNo
17793276MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOFJuly 2022May 2025Allow3400YesNo
17859015CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOFJuly 2022November 2024Allow2820NoNo
17835041CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERSJune 2022June 2025Allow3621YesNo
17835081CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERSJune 2022February 2025Allow3221NoNo
17835395CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERSJune 2022May 2025Allow3511NoNo
17835311CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERSJune 2022July 2025Allow3721NoNo
17830781DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCERJune 2022August 2024Allow2720NoNo
17749953ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATESMay 2022March 2025Abandon3420NoNo
17733974BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USESApril 2022March 2025Allow3501NoNo
17697583B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATESMarch 2022April 2025Allow3731YesYes
17553745ANTIBODY DRUG CONJUGATESDecember 2021May 2025Allow4111YesNo
17549586COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1December 2021June 2025Abandon4211NoNo
17546706HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOFDecember 2021October 2024Abandon3410NoNo
17531343GLYCOSIDE DUAL-CLEAVAGE LINKERS FOR ANTIBODY-DRUG CONJUGATESNovember 2021August 2024Allow3330YesNo
17598064SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAMESeptember 2021April 2025Allow4211YesNo
17469799METHODS FOR MANUFACTURING PHTHALOCYANINE DYE CONJUGATES AND STABLE CONJUGATESSeptember 2021April 2025Allow4321YesNo
16644842ANTI-MESOTHELIN ANTIBODY AND ANTIBODY DRUG CONJUGATE THEREOFAugust 2021August 2024Allow5310NoNo
17431059COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR NEOVASCULARIZATIONAugust 2021April 2025Allow4411NoNo
17424528COMPOUND FOR PREPARATION OF ANTIBODY-PAYLOAD CONJUGATE AND USE THEREOFJuly 2021January 2025Allow4220NoNo
17374756ANTIBODY DRUG CONJUGATES WITH ENZYMATICALLY CLEAVABLE GROUPSJuly 2021July 2024Allow3630YesNo
17358306ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIESJune 2021June 2024Allow3521NoNo
17309778CONTROLLED FUCOSYLATION OF ANTIBODIESJune 2021February 2025Abandon4411NoNo
17341606PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINSJune 2021October 2024Abandon4001NoNo
17331290Glycan-Interacting Compounds and Methods of UseMay 2021May 2025Abandon4702NoNo
17295420BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTSMay 2021September 2024Allow4020NoNo
17291141FILTERABLE DUOCARMYCIN-CONTAINING ANTIBODY-DRUG CONJUGATE COMPOSITIONS AND RELATED METHODSMay 2021August 2024Allow3920YesNo
17290694ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOFApril 2021November 2024Abandon4301NoNo
17284388COMPOUNDS AND THERAPEUTIC USES THEREOFApril 2021January 2025Allow4611YesNo
17210081ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USEMarch 2021March 2025Allow4821NoYes
17044659NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOFMarch 2021January 2025Allow5221YesNo
17276324ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOFMarch 2021July 2024Allow4001YesNo
17176326PROCESS FOR PRODUCING ALKALI TAURINATEFebruary 2021April 2025Abandon5011NoNo
17262157NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAMEJanuary 2021July 2024Allow4210YesNo
17260901LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USEJanuary 2021August 2024Allow4311YesNo
17258250PROTEIN-BASED MICELLES FOR THE DELIVERY OF HYDROPHOBIC ACTIVE COMPOUNDSJanuary 2021June 2025Abandon5402NoNo
17135946METHODS FOR TREATING AND REDUCING TRAUMATIC BRAIN INJURY- ASSOCIATED IMPAIRMENTS USING SGP130December 2020April 2025Allow5231YesNo
16945163USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)-KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAINJuly 2020June 2025Abandon5841NoYes
16941383LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USEJuly 2020March 2025Abandon5511NoNo
16921528Modified Antibody, Antibody-Conjugate and Process For The Preparation ThereofJuly 2020August 2024Allow5021YesNo
16486862CD20-TARGETED ANTIBODY COUPLING PHARMACEUTICAL PREPARATIONFebruary 2020February 2025Allow6050NoNo
16639499PROGRAMMABLE DENDRITIC DRUGSFebruary 2020February 2025Allow6061NoNo
16694283METHOD OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) STABILIZATIONNovember 2019July 2024Allow5660YesNo
16348749CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERSMay 2019March 2025Allow6081YesNo
16302270USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCERNovember 2018January 2022Abandon3861YesNo
16096631PYRROLOBENZODIAZEPINE CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCEROctober 2018September 2019Allow1110NoNo
16095262DIMERIC COMPOUNDSOctober 2018April 2019Allow500YesNo
16162158COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERSOctober 2018December 2018Allow900YesNo
16076588PYRROLOBENZODIAZEPINE CONJUGATESAugust 2018February 2020Allow1820NoNo
15765685ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFApril 2018November 2024Abandon6081YesNo
15764100CRYSTALLINE AND AMORPHOUS FORMS OF 17-ALPHA-HYDROXYPROGESTERONE CAPROATEMarch 2018October 2019Allow1911YesNo
15678281OXYGEN GENERATING BIOMATERIALAugust 2017September 2019Allow2520NoNo
15527129COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORSMay 2017December 2019Allow3140YesNo
15514928PREDICTION OF RESPONSE TO PARP INHIBITORS AND COMBINATIONAL THERAPY TARGETING C-MET AND PARP1March 2017June 2019Allow2601YesNo
13499724PROCESS FOR PREPARATION OF DIETHYLENETRIAMINEPENTAACETIC ACID DERIVATIVE, AND DIETHYLENETRIAMINEPENTAACETIC ACID DERIVATIVEApril 2012May 2013Allow1410NoNo
13409657PROCESS FOR PREPARING POLYISOCYANATES COMPRISING BIURET GROUPSMarch 2012August 2013Allow1711NoNo
13396884SYSTEMS FOR ALKYL ESTER PRODUCTIONFebruary 2012February 2013Allow1211NoNo
13368601ANHYDRIDE DERIVATIVES OF 2-(S)-(6-METHOXY-2-NAPHTYL)-PROPANOIC ACID, PREPARATION METHOD AND USE THEREOFFebruary 2012August 2013Allow1810NoNo
13341311PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACIDDecember 2011July 2012Allow710NoNo
13141325PROCESS FOR PRODUCING ACRYLIC ACIDJune 2011November 2012Allow1730YesNo
13059766METAL COMPLEX AND MANUFACTURING METHOD THEREFORMay 2011September 2013Allow3011NoNo
13125895PROCESS FOR PREPARING ISOCYANATESApril 2011March 2013Allow2300NoNo
12741247PROCESS FOR THE SYNTHESIS OF A PROPARGYLIC ALCOHOLMarch 2011September 2011Allow1700NoNo
13038472METHOD FOR PRODUCING A PERFLUORO COMPOUND HAVING HYDROXYL GROUPSMarch 2011April 2013Allow2520YesNo
12666773Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and DiseaseJanuary 2011December 2012Allow3640YesNo
12969013NATEGLINIDE CRYSTALSDecember 2010March 2011Allow300NoNo
12867055NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERSOctober 2010February 2012Allow1800NoNo
12908583PROCESS FOR THE PREPARATION OF PHENOLOctober 2010April 2012Allow1811NoNo
12921495METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDSSeptember 2010April 2012Allow2010NoNo
12918391SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALSAugust 2010October 2012Allow2610NoNo
12863033METHOD FOR PREPARING (METH)ACRYLIC ANHYDRIDEAugust 2010September 2011Allow1400NoNo
12823338PROCESS FOR PREPARING FORMIC ACIDJune 2010December 2012Allow3020NoYes
12735121CARBONYLATION PROCESS FOR THE PRODUCTION OF METHYL ACETATEJune 2010February 2013Allow3210NoNo
12735214NOVEL COMPOUNDS USEFUL IN THERAPEUTIC AND COSMETIC METHODSJune 2010April 2013Allow3421NoNo
12816701BIOBASED POLYESTERSJune 2010January 2013Allow3112NoNo
12766162(3R)-L-MENTHYL 3-HYDROXYBUTYRATE, PROCESS FOR PRODUCING THE SAME, AND SENSATE COMPOSITION COMPRISING THE SAMEApril 2010March 2013Allow3521YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PUTTLITZ, KARL J.

Strategic Value of Filing an Appeal

Total Appeal Filings
21
Allowed After Appeal Filing
10
(47.6%)
Not Allowed After Appeal Filing
11
(52.4%)
Filing Benefit Percentile
74.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 47.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner PUTTLITZ, KARL J - Prosecution Strategy Guide

Executive Summary

Examiner PUTTLITZ, KARL J works in Art Unit 1646 and has examined 303 patent applications in our dataset. With an allowance rate of 93.1%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner PUTTLITZ, KARL J's allowance rate of 93.1% places them in the 80% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PUTTLITZ, KARL J receive 1.73 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PUTTLITZ, KARL J is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +5.1% benefit to allowance rate for applications examined by PUTTLITZ, KARL J. This interview benefit is in the 30% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.2% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 48.1% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 78.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 52.2% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 30.7% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.4% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.